These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30723480)

  • 1. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
    Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
    Front Immunol; 2018; 9():3162. PubMed ID: 30723480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
    Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
    EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
    Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
    EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
    Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
    J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells.
    Boucau J; Das J; Joshi N; Le Gall S
    PLoS Pathog; 2020 Mar; 16(3):e1008442. PubMed ID: 32196533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
    Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
    J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
    Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
    Jones RB; Mueller S; O'Connor R; Rimpel K; Sloan DD; Karel D; Wong HC; Jeng EK; Thomas AS; Whitney JB; Lim SY; Kovacs C; Benko E; Karandish S; Huang SH; Buzon MJ; Lichterfeld M; Irrinki A; Murry JP; Tsai A; Yu H; Geleziunas R; Trocha A; Ostrowski MA; Irvine DJ; Walker BD
    PLoS Pathog; 2016 Apr; 12(4):e1005545. PubMed ID: 27082643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8
    Khoury G; Kulpa DA; Parsons MS
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
    Sung JA; Sholtis K; Kirchherr J; Kuruc JD; Gay CL; Nordstrom JL; Bollard CM; Archin NM; Margolis DM
    EBioMedicine; 2017 Sep; 23():52-58. PubMed ID: 28803740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill.
    Kristoff J; Rinaldo CR; Mailliard RB
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31905690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection.
    Mann JFS; Pankrac J; Klein K; McKay PF; King DFL; Gibson R; Wijewardhana CN; Pawa R; Meyerowitz J; Gao Y; Canaday DH; Avino M; Poon AFY; Foster C; Fidler S; Shattock RJ; Arts EJ
    EBioMedicine; 2020 Sep; 59():102853. PubMed ID: 32654992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
    Macedo AB; Levinger C; Nguyen BN; Richard J; Gupta M; Cruz CRY; Finzi A; Chiappinelli KB; Crandall KA; Bosque A
    J Virol; 2022 Aug; 96(15):e0037222. PubMed ID: 35867565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
    Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4
    Kulpa DA; Talla A; Brehm JH; Ribeiro SP; Yuan S; Bebin-Blackwell AG; Miller M; Barnard R; Deeks SG; Hazuda D; Chomont N; Sékaly RP
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell toxicity of HIV latency reversing agents.
    Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
    Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
    Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
    Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.
    Yang H; Buisson S; Bossi G; Wallace Z; Hancock G; So C; Ashfield R; Vuidepot A; Mahon T; Molloy P; Oates J; Paston SJ; Aleksic M; Hassan NJ; Jakobsen BK; Dorrell L
    Mol Ther; 2016 Nov; 24(11):1913-1925. PubMed ID: 27401039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.